IPIX Innovation Pharmaceuticals Inc

Innovation Pharmaceuticals Announces Pre-IND Meeting Request Granted by FDA for the Study of Brilacidin for the Treatment of COVID-19

Innovation Pharmaceuticals Announces Pre-IND Meeting Request Granted by FDA for the Study of Brilacidin for the Treatment of COVID-19
EN
02/10/2020

Underlying

IPIXInnovation Pharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Innovation Pharmaceuticals Inc

 PRESS RELEASE
Free
IPIX Innovation Phar...

Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track...

Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024 WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleased to provide shareholders with an update on recent progress in the development of BeaMed’s groundbreaking StingRay Laser System (the “System”). BeaMed is a pioneering company dedicated to revolutionizing epilepsy and cancer surgery through laser-based...

August 28, 2023 1 EN
 PRESS RELEASE
Free
IPIX Innovation Phar...

Innovation Pharmaceuticals Provides Update on U.S. Patent Applications...

Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases WAKEFIELD, MA, June 21, 2023 (GLOBE NEWSWIRE) -- via – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the United States Patent and Trade Office (USPTO), on June 6, 2023, granted a patent, “Host Defense Protein (HDP) Mimetics for Prophylaxis and/or Treatment of Inflammatory Diseases of the Gastrointestinal Tract,” and also recently issued a Notice of Allowanc...

June 21, 2023 1 EN
 PRESS RELEASE
Free
IPIX Innovation Phar...

Innovation Pharma Announces BeaMed Technologies Breakthrough in Develo...

Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing WAKEFIELD, MA, June 05, 2023 (GLOBE NEWSWIRE) -- via Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company and minority stakeholder in BT BeaMed Technologies (“BeaMed”), is pleased to inform shareholders that BeaMed, a pioneering company dedicated to revolutionizing epilepsy and cancer surgery through laser-based innovations, reported significant progress in the developme...

June 5, 2023 1 EN
 PRESS RELEASE
Free
IPIX Innovation Phar...

Innovation Pharmaceuticals Brilacidin Antifungal Research Published in...

Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications WAKEFIELD, MA, April 17, 2023 (GLOBE NEWSWIRE) -- via -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced publication of Brilacidin antifungal research in Nature Communications, a leading peer-reviewed scientific journal. The paper, discussing combinations of Brilacidin and other antifungal drugs toward improving treatment outcomes in fungal infections, is available at the link below: dos Reis, T.F., de Castro, P.A., Bastos, R.W...

April 17, 2023 1 EN
 PRESS RELEASE
Free
IPIX Innovation Phar...

Innovation Pharmaceuticals Announces New Antifungal Testing of Brilaci...

Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers WAKEFIELD, MA, March 15, 2023 (GLOBE NEWSWIRE) -- via – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that based on positive findings new testing of Brilacidin in additional in vitro and in vivo models against hard-to-treat fungal pathogens is planned by NIH/NIAID-affiliated and other academic researchers. Brilacidin is the Company’s defensin mimetic drug candidate exhibiting antimicrobial an...

March 15, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch